



**acer**therapeutics

**Developing Therapeutics for the Treatment of  
Serious Rare and Life-Threatening Diseases with  
Significant Unmet Medical Needs**



**Corporate Presentation**

March 1, 2021

Nasdaq: ACER

# Forward-looking Statements

---

This presentation contains “forward-looking statements” that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this presentation regarding strategy, future operations, timelines, future financial position, future revenues, projected expenses, regulatory submissions, actions or approvals, cash position, liquidity, prospects, plans and objectives of management are forward-looking statements. Examples of such statements include, but are not limited to, statements relating to the potential for our product candidates to safely and effectively treat diseases and to be approved for marketing; the commercial or market opportunity of any of our product candidates in any target indication and any territory; our ability to secure the additional capital necessary to fund our various product candidate development programs; the adequacy of our capital to support our future operations and our ability to successfully fund, initiate and complete clinical trials and regulatory submissions; the ability to protect our intellectual property rights; our strategy and business focus; and the development, expected timeline and commercial potential of any of our product candidates. We may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking statements and you should not place undue reliance on these forward-looking statements. Such statements are based on management’s current expectations and involve risks and uncertainties. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors, including, without limitation, risks and uncertainties associated with the ability to project future cash utilization and reserves needed for contingent future liabilities and business operations, the availability of sufficient resources to fund our various product candidate development programs and to meet our business objectives and operational requirements, the fact that the results of earlier studies and trials may not be predictive of future clinical trial results, the protection and market exclusivity provided by our intellectual property, the substantial costs and diversion of management’s attention and resources which could result from pending securities litigation, risks related to the drug development and the regulatory approval process, including the timing and requirements of regulatory actions, and the impact of competitive products and technological changes. We disclaim any intent or obligation to update these forward-looking statements to reflect events or circumstances that exist after the date on which they were made. You should review additional disclosures we make in our filings with the Securities and Exchange Commission, including our Quarterly Reports on Form 10-Q and our Annual Report on Form 10-K. You may access these documents for no charge at <http://www.sec.gov>.

# Corporate Overview

Acer Therapeutics is a pharmaceutical company that acquires, develops and seeks to commercialize therapies for serious rare and life-threatening diseases with significant unmet medical needs

- Headquartered: **Newton, MA**
- Headcount: **20**
- Founded: **December 2013**
- Public: **September 2017**
- Cash: \$5.8M as of December 31, 2020, combined with additional:
  - \$3.2M of net proceeds subsequently received from ATM stock sales and Lincoln Park stock purchase agreement as of March 1, 2021
  - \$1.0M nonrefundable payment and \$4.0M secured loan received from Relief Therapeutics on January 26, 2021 as per the ACER-001 Option Agreement
- Expected to have sufficient capital to fund current operations into Q3 2021

# Leadership Team

Chris Schelling <b>CEO &amp; Founder</b>	<ul style="list-style-type: none"> <li>• 21 years; strategic commercial development &amp; orphan</li> </ul>	
Harry Palmin <b>Chief Operating &amp; Financial Officer</b>	<ul style="list-style-type: none"> <li>• 25+ years; corporate &amp; finance experience</li> </ul>	
Matt Seibt <b>Chief Commercial Officer</b>	<ul style="list-style-type: none"> <li>• 22 years; sales, market access &amp; product launch</li> </ul>	
Jeff Davis <b>Chief Business Officer</b>	<ul style="list-style-type: none"> <li>• 25+ years; business &amp; corporate development</li> </ul>	
John Klopp <b>Chief Technical Officer</b>	<ul style="list-style-type: none"> <li>• 18 years; orphan manufacturing &amp; commercialization</li> </ul>	
Don Joseph, JD <b>Chief Legal Officer &amp; Secretary</b>	<ul style="list-style-type: none"> <li>• 25+ years; general counsel &amp; senior management</li> </ul>	
Stacey Bain, Ph.D. <b>VP, Clinical Operations</b>	<ul style="list-style-type: none"> <li>• 22 years; clinical operations &amp; drug development</li> </ul>	
Renee Carroll <b>VP, Regulatory Affairs</b>	<ul style="list-style-type: none"> <li>• 25+ years; regulatory affairs, all phases of development</li> </ul>	

# Investment Highlights

- Acer's pipeline includes four programs:
  - **ACER-001** (a taste-masked, immediate release formulation of sodium phenylbutyrate) for the treatment of various inborn errors of metabolism, including urea cycle disorders (UCDs) and Maple Syrup Urine Disease (MSUD)
  - **EDSIVO™** (celiprolol) for the treatment of vascular Ehlers-Danlos syndrome (vEDS) in patients with a confirmed type III collagen (COL3A1) mutation
  - **ACER-801** (osanetant) for the treatment of induced Vasomotor Symptoms (iVMS)
  - **ACER-2820** (emetine) a host-directed therapy against a variety of infectious diseases
- Product candidates are believed to present a comparatively de-risked profile, having one or more of:
  - Favorable safety profile; clinical proof-of-concept data; mechanistic differentiation
  - Potential expedited paths for development through specific FDA-established programs
- Multiple anticipated key milestones:
 

✓ ACER-001 BE fed trial completed:	<b>Q1 2021</b>
• ACER-001 pre-NDA meeting with FDA*:	<b>Q2 2021</b>
• EDSIVO™ FDA meeting to discuss confirmatory evidence plan:	<b>Q2 2021</b>
• ACER-001 (UCDs) NDA submission**:	<b>Mid-2021</b>
• Osanetant IND submission:	<b>Q3 2021</b>
• Osanetant Phase 2 trial initiation***\$:	<b>Q4 2021</b>

\* Assuming successful completion of the ongoing development activities

\*\* Provided no additional data is requested by the FDA during pre-NDA meeting and ongoing development activities are successfully completed (including evaluation of long-term product stability data)

\*\*\* Subject to successful IND submission and clearance

\$ Subject to additional capital

# Clinical Pipeline

Program / Indication	Novel MOA / Unique Characteristics	Preclinical	Phase 1	Phase 2	Phase 3
ACER-001 (sodium phenylbutyrate)					
Urea Cycle Disorders	Nitrogen scavenger				
Maple Syrup Urine Disease	Inhibition of BCKD kinase to increase BCAA metabolism	\$			
EDSIVO™ (celiprolol)					
vascular Ehlers-Danlos syndrome (COL3A1+)	Induces vascular dilatation and smooth muscle relaxation	*			
ACER-801 (osanetant)					
Induced Vasomotor Symptoms (iVMS)	Neurokinin 3 Receptor Antagonist	\$			
ACER-2820 (emetine)					
Broad-spectrum Antiviral	Host-directed Therapy	\$			

\$ Additional capital resources required to fund these programs going forward

\*Response received March 2020 denying appeal of the Complete Response Letter but describing possible paths forward for Acer to explore that could provide the substantial evidence of effectiveness needed to support a potential resubmission of the EDSIVO™ NDA

# Overview

## Disease Overview

- **UCDs**: A group of metabolic genetic diseases that lead to toxic build-up of  $\text{NH}_4^+$
- **UCDs**: Currently treated with RAVICTI<sup>®</sup>, BUPHENYL<sup>®</sup>, AMMONUL<sup>®</sup>, and a highly-restricted diet
- **MSUD**: A metabolic genetic disease that leads to toxic build-up of leucine and other branched-chain amino acids
- **MSUD**: Currently managed with a highly-restricted diet; poor compliance

## Mechanism of Action

- **Small molecule with unique MOAs in various disorders**
- **UCDs**: NaPB is a prodrug of phenylacetate, a  $\text{NH}_4^+$  scavenger
- **MSUD**: NaPB is an allosteric inhibitor of BCKD kinase

## Product Profile

- **Taste-masked, immediate release formulation of sodium phenylbutyrate**
- **UCDs**: Bioequivalence trials showed ACER-001 has similar relative bioavailability to BUPHENYL<sup>®</sup> in healthy volunteers under both fasted and fed conditions
- ACER-001 under fasted conditions achieved  $>2\times C_{\text{max}}$  of PBA vs. fed conditions
- **MSUD**: POC study<sup>1</sup> suggests ~60% of patients have 30% reduction in Leucine


## The Opportunity

- **Anticipate NDA submission for UCDs Mid-2021\***
- **UCDs**: ~700 patients treated with sodium / glycerol phenylbutyrate.
- **MSUD**: ~800 treatment-eligible patients in the U.S.; 3,000 patients worldwide
- Advantageous orphan pricing likely with robust program to support patient access and reimbursement

# Urea Cycle Disorders

- Newborns with severe urea cycle disorders become significantly ill with symptoms that mimic sepsis -- failure to feed, lethargy, respiratory distress, seizures and ultimately coma
- Children and adults with milder (or partial) urea cycle enzyme deficiencies may go years without a diagnosis, until a trigger -- a high protein meal, viral illness, excessive exercise or calorie deficiency -- causes excessive ammonia to be produced in the body, resulting in critical elevations of blood ammonia levels
- For individuals with an ornithine transcarbamylase (OTC) deficiency, typical neuropsychological complications include developmental delay, learning disabilities, intellectual disability, attention deficit hyperactivity disorder (ADHD), and executive function deficits

## Symptoms of Hyperammonemia




Reproduced from:  
[http://upload.wikimedia.org/wikipedia/commons/7/76/Symptoms\\_of\\_hyperammonemia.svg](http://upload.wikimedia.org/wikipedia/commons/7/76/Symptoms_of_hyperammonemia.svg).

# Mechanism of Action

## Nitrogen scavenger therapy

- Alternative pathway treatment diverts nitrogen from the urea cycle to alternate routes of excretion
- Both RAVICTI® and BUPHENYL® metabolize to phenylbutyrate (PBA), a prodrug of phenylacetate (PAA)
- **PAA is the active moiety** – it combines with glutamine, producing phenylacetylglutamine
- Phenylacetylglutamine (PAGN) is excreted by the kidneys



**Fig. 1.** Metabolizing pathway and mechanism of action of GPB. GPB (glycerol phenylbutyrate); PAA (phenylacetic acid); PBA (phenylbutyric acid); PAGN (phenylacetylglutamine).

# Unmet Need

- **BUPHENYL®:** Foul odor and foul/bitter taste; considered unpalatable<sup>1</sup>
  - 64% of patients reported it is difficult to take because of taste
  - Physicians reported that 25-33% of patients took less than target dose due to tolerability
  - Only 25% of patients indicated that they never miss a dose
  - 46% of patients reported taste as the reason for discontinuation<sup>1</sup>
- **RAVICTI®:** Tasteless/Odorless
  - 75% of BUPHENYL® patients switched to RAVICTI®<sup>3</sup>
  - Pricing has risen to levels considered challenging<sup>3</sup>
  - Reports of difficult access, unaffordability, and forced switches back to sodium phenylbutyrate
    - Example: BUPHENYL® and RAVICTI® blocked on JPMorgan Chase plan Rx formulary<sup>2</sup>
  - Some patients are not meeting the treatment goal of <0.5 ULN (~17.5 umol/L)<sup>4</sup>
  - Patients and physicians desire a taste-masked, effective, and affordable treatment option<sup>3</sup>

1 Shchelochkov et al., Molecular Genetics and Metabolism Reports 8 (2016) 43-47.

2 [https://www.caremark.com/portal/asset/Formulary\\_Drug\\_Removals\\_JPMC.pdf](https://www.caremark.com/portal/asset/Formulary_Drug_Removals_JPMC.pdf)

3 Acer Market Research

4 Nicola Longo & Robert J. Holt (2017) Expert Opinion on Orphan Drugs, 5:12, 999-1010.



# Development Overview

- Regulatory Path: 505(B)(2) → RLD: BUPHENYL®
- Bridging Studies: two (2) studies
  - Fasted (pre-meal) study: lifecycle opportunity **[completed]**
  - Fed study: expected to be on label at launch **[completed]**
- Taste Assessment Studies: two (2) studies
  - At 5 and 10-minutes **[completed]**
  - At 0 through 5-minutes **[completed]**
- Chronic (9-month) Toxicity Studies: two (2) studies
  - Talc & Eudragit E **[completed]**
- 12-month Stability **[ongoing → completion Q2 2021]**



# Food Effect

- Maximum concentration ( $C_{max}$ ) ~2x higher under fasted (pre-meal) conditions
- Comparable PK between ACER-001 and NaPB under fed conditions\*

## ACER-001<sup>1</sup>



## NaPB<sup>2</sup>



\* Based on data comparison of ACER-001 under fed conditions vs. published data of NaPB under fed conditions


1 ACER-001 Pivotal BE/BA Study (Part B) in healthy volunteers

2 Sci Rep 9, 17075 (2019). <https://doi.org/10.1038/s41598-019-53628-x>

# Food Effect: In Silico Model


## Adult Virtual Patient

**PAA**  
(Safety<sup>1,2,3</sup>)



**uPAGN**  
(Efficacy)

## Child Virtual Patient



- ACER-001 in a fasted state required ~30% less PBA to achieve comparable therapeutic benefit in a fed state
- Model predicted 43% increase in urinary PAGN levels (negative correlation with blood ammonia AUC)

# Food Effect: Summary

- Dosing and Administration for BUPHENYL<sup>®</sup>, RAVICTI<sup>®</sup> and Pheburane<sup>®</sup> are all instructed to be given with food
  - There is a significant food effect with NaPB
  - The pharmacokinetic (PK) and pharmacodynamic (PD) properties of RAVICTI<sup>®</sup> are indistinguishable in the fed or fasted states<sup>1</sup>
- Dosing in a pre-meal setting should increase exposure, and theoretically improve ammonia control / outcomes in UCDs patients
- 2x the  $C_{max}$  of PBA may also improve efficacy in other disorders (where PBA is the active moiety), such as MSUD and PFIC<sup>2</sup>
- ACER-001's formulation may improve tolerability of the drug when administered under fasted (pre-meal) conditions

# Product Differentiation

Phenylbutyrate Formulations			
	ACER-001*	RAVICTI®	BUPHENYL®
Efficacy / Safety in UCDs	✓	✓	✓
Palatability / Compliance	✓	✓	X**
Pricing (Per Patient Per Year)	TBD, likely near BUPHENYL®	\$166k-\$1.3M*** (avg ~\$900K)	\$200k-\$400k*** (avg ~\$300K)
Formulation	Multi-Particulate (Sachet)	Oil (Tablespoons)	Powder/Tablets (up to 40 tablets/day)


# Clinical & Regulatory Paths

- ✓ BE trial under fasted conditions completed in Q1 2020
- ✓ Received FDA Type C meeting feedback in August 2020
- ✓ BE trial under fed conditions completed in Q1 2021
- Targeting pre-NDA meeting with FDA in Q2 2021
- 505(b)(2) NDA for UCDs: anticipate submission mid-2021 provided no additional data is requested by the FDA during pre-NDA meeting and ongoing development activities are successfully completed
- Evaluate in parallel<sup>§</sup> or after initial potential FDA approval for UCDs (under fed conditions):
  - Pre-meal administration of ACER-001, which would require additional nonclinical and clinical studies<sup>§</sup> to demonstrate efficacy and safety in UCDs
  - MSUD
  - Other potential indications

# Value Proposition

## ACER-001 Value Proposition:

- Taste-masked formulation improves palatability & tolerability vs BUPHENYL®
- Bioequivalence trials showed ACER-001 has similar relative bioavailability to BUPHENYL® under both fasted and fed conditions
- New fasted (pre-meal) dosing data suggests ability to optimize Rx dosing approach<sup>2</sup>
- Pricing significantly lower than current RAVICTI® price
- Robust patient support services program to remove barriers to care
- Payer engagement strategy to alleviate insurance paperwork and support switching
- Acer's commitment to support the UCD community and on-going IEM research



# IP / Exclusivities

- IP:
  - Filed formulation composition of matter patent application (priority date Oct. 2016)
  - Issued patents (US/EP): “Methods of modulation of branched chain acids and uses thereof” [US PATENT NO. 10,092,532], licensed from Baylor College of Medicine relating to MSUD
  - In addition, we continue to pursue new patents and exclusivity possibilities, based on our development plans and product attributes
- Regulatory Exclusivities:
  - MSUD: Granted U.S. Orphan Drug Designation: 7 years market exclusivity from FDA approval
  - Pediatric exclusivity: +6 months added (if pediatric indication study approved)

# Option Agreement with Relief Therapeutics

- ✓ Option Agreement announced January 25, 2021
- ✓ Acer received \$1.0M payment and a \$4.0M secured loan from Relief
- ✓ Relief (SIX: RLF, OTCQB: RLFTF) received exclusivity to negotiate ACER-001 collaboration and license agreement through June 30, 2021
- Terms of the proposed collaboration and license agreement\*
  - Upon execution, Acer will receive \$14.0M in cash (net \$10.0M, offset by repayment of \$4.0M loan)
  - Relief to pay up to \$20.0M in U.S. development and commercial launch costs for the UCDs and MSUD indications
  - Acer will retain development and commercialization rights in the U.S., Canada, Brazil, Turkey and Japan. Split net profits from Acer's territories 60:40 in favor of Relief
  - Relief will also license the rights for the rest of the world – Acer will receive 15% net sales royalty on all revenues in Relief's territories. Acer could also receive up to \$6.0M in EU for UCDs and MSUD approvals

\* There can be no assurance, however, that a definitive agreement will be successfully negotiated and executed between the parties on these terms, on other mutually acceptable terms, or at all. Except for the \$1.0M upfront payment to Acer and the \$4.0M one-year secured loan from Relief to Acer, the remaining proposed terms of the collaboration are not binding and are subject to change as a result of further diligence by Relief and negotiation of a definitive collaboration and license agreement between the parties

# Overview

## Disease Overview

- **No approved therapeutic options for vEDS patients**
- Autosomal dominant connective tissue disorder of collagen synthesis caused by mutations in the COL3A1 gene for type III procollagen
- Characterized by arterial aneurysms, dissections and/or ruptures
- Median survival in the U.S. is estimated to be 51 years of age

## Mechanism of Action

- **EDSIVO™ has a unique pharmacological profile**
- $\beta_2$  and  $\beta_3$  adrenergic receptor agonist; selective  $\beta_1$  and  $\alpha_2$  adrenergic receptor antagonist; activates endothelial Nitric Oxide Synthase (eNOS)
- EDSIVO's™ potential beneficial effects in vEDS thought to be through vascular dilatation and smooth muscle relaxation, thereby reducing the mechanical stress on collagen fibers within the arterial wall

## Product Profile

- **BBEST Clinical Trial: 76% reduction in risk of arterial events observed in COL3A1+ subpopulation<sup>1</sup>**
- Statistically-significant improvement in event-free survival (EFS) compared to control in vEDS patients (n=53)<sup>1</sup>

## The Opportunity

- **FDRR appeal of CRL denied; currently exploring possible path forward**
- In February 2021 submitted a meeting request with FDA regarding Acer's proposed plan to support celiprolol's potential benefit in treating COL3A1+ vEDS patients<sup>§</sup>
- Could potentially satisfy the substantial evidence of effectiveness needed to support a possible resubmission of the EDSIVO™ NDA<sup>§</sup>
- Neither resubmission nor the prospect of approval of EDSIVO™ NDA is assured

# Vascular Ehlers-Danlos Syndrome (vEDS)

- Ehlers-Danlos syndrome (EDS) is a group of hereditary disorders of connective tissue
- vEDS (EDS type IV) is the severe subtype:
  - Characterized by aneurysms, dissections and/or ruptures
    - Vascular
    - Hollow Organs (e.g. gastrointestinal, uterine)
  - Autosomal dominant (50%); spontaneous mutations (50%)
  - Diagnosed by clinical symptoms and confirmed by presence of mutations in the COL3A1 gene
  - Events occur in 25% of patients before the age of 20, and 90% by the age of 40
  - Median age of death is estimated to be 51 years<sup>1</sup>
- No approved therapeutic options for vEDS
  - Current treatment is focused on surgical intervention





Fig. 3 Distribution of 132 vascular complications in 24 patients with a clinical diagnosis of EDS type IV. J Vasc Surg 2005;42:98-106.

# Mechanism of Action


- EDSIVO™ has a unique pharmacological profile:
  - $\beta_2$  and  $\beta_3$  adrenergic receptor agonist
  - Selective  $\beta_1$  and  $\alpha_2$  adrenergic receptor antagonist
  - Intrinsic sympathomimetic activity (ISA+)
  - Lacks non-specific membrane effects
  - Activates endothelial Nitric Oxide Synthase (eNOS)\*
- Void of blood pressure lowering in normotensive people
  - Most vEDS patients are normotensive, thus the potential beneficial effect of celiprolol is unlikely to be through blood pressure lowering ( $\beta_1$  antagonism)
- EDSIVO's™ mechanism of action in vEDS patients is thought to be through vascular dilatation and smooth muscle relaxation, thereby reducing the mechanical stress on collagen fibers within the arterial wall



# BBEST Trial: COL3A1+ Subpopulation

## Efficacy:

- 76% reduction in the risk of fatal or nonfatal cardiac or arterial events in COL3A1+ EDSIVO™ patients vs. control group over mean follow-up of 47 months
- 75% reduction in risk of primary (cardiac or arterial events) and secondary (intestinal or uterine rupture) events in COL3A1+ EDSIVO™ patients vs. control group




**Figure 3: Kaplan-Meier curves of event-free survival in 33 patients with positive COL3A1 mutation**  
Primary endpoint (A). Primary and secondary endpoints (B).

# Regulatory Timeline

- **June 2019:** Received CRL from FDA
  - CRL stated it will be necessary to conduct an adequate and well-controlled trial to determine whether celiprolol reduces the risk of clinical events in patients with vEDS
- **December 2019:** Submitted Formal Dispute Resolution Request (FDRR) to the Office of New Drugs (OND)
- **March 2020:** Received OND FDRR response
  - Denied appeal of CRL
  - OND described possible paths forward for Acer to explore that could provide substantial evidence of effectiveness needed to support a potential resubmission of NDA
- **February 2021:** Pursuing next steps
  - Submitted a meeting request with FDA regarding Acer's proposed plan to support celiprolol's potential benefit in treating COL3A1+ vEDS patients
  - Could potentially satisfy the substantial evidence of effectiveness needed to support a possible resubmission of the EDSIVO™ NDA<sup>§</sup>
- The company may discontinue the process at any point where risk/benefit no longer justifies continued resources

# Substantial Evidence of Effectiveness

## THE QUANTITY OF CLINICAL EVIDENCE TO ESTABLISH EFFECTIVENESS



# Overview

## Disease Overview

- **iVMS are well documented with the use of cancer therapies and certain surgical procedures**
- Symptoms such as hot flashes can appear immediately and be severe after reduction in estrogen production or estrogen blockade
- KNDy neurons are important for thermoregulation and become hypertrophied in the absence of estrogen

## Mechanism of Action

- **Osanetant is a selective, non-peptide tachykinin NK3 receptor antagonist**
- NK3R is the main receptor for neurokinin B (NKB), a tachykinin peptide primarily found in the arcuate nucleus (ARC) of the hypothalamus and KNDy neurons
- NK3R antagonism is an alternative to hormone replacement therapy for the treatment VMS by mimicking the negative feedback of estrogen on KNDy neurons

## Product Profile

- **Believed to have largest body of clinical safety data for any NK3R antagonist**
- Clinical and laboratory safety results are available from 23 completed Phase 1 and 2 studies (387 healthy subjects and 822 patients were treated with osanetant)\*
- Oral bioavailability, readily crosses the blood-brain barrier

## The Opportunity

- **Acer licensed worldwide rights to osanetant from Sanofi in Dec. 2018**
- Targeting IND submission in Q3 2021
- Plan to initiate Phase 2 trial in Q4 2021\*\*
- Currently no other NK3R antagonists in development in iVMS space

# History

- Acer acquired worldwide rights to osanetant from Sanofi in December 2018
- Osanetant (SR142801) was the first selective non-peptide tachykinin NK3 receptor antagonist evaluated as a potential treatment for schizophrenia
- Clinical and laboratory safety results are available from 23 completed Phase 1 and 2 studies in which 387 healthy subjects and 822 patients (schizophrenia, depression, others) were treated with osanetant
- No major safety concerns identified from these studies after single-dose and repeated-dose administration of up to 400 mg QD for up to 21 days, and 200 mg QD for up to 6 weeks for schizophrenia
- In March 2005, Sanofi-Aventis discontinued the development of osanetant for schizophrenia citing 'lack of efficacy compared with placebo' in this indication as a major reason for this decision



# Induced Vasomotor Symptoms (iVMS)

## Women who are BRCA+ and have prophylactic bilateral salpingo-oophorectomy (PBSO)

- 67% of women have symptoms of menopause such as hot flashes<sup>5</sup>
- Up to 35% complain of “extremely bothersome” symptoms up to two years after their surgery<sup>6</sup>

## Men with HR+ Prostate Cancer (CaP) receiving Leuprolide

- 80% of men experience hot flashes<sup>3</sup>
- 15-27% of patients consider hot flashes the most distressing side effect
- 30-40% experienced moderate-to-severe symptoms
- 20% discontinued or disrupted treatment

## Women with HR+ Breast Cancer (CaB) receiving Tamoxifen

- 84% of women experienced hot flashes<sup>1</sup>
- 80% experienced night sweats
- 60% experienced severe symptoms
- Symptoms persisted throughout 5 years of treatment and were mainly attributed to tamoxifen
- After 4.5 years, 46% of women had discontinued tamoxifen<sup>2</sup>

<sup>1</sup>Moon, Z. et al., JOURNAL OF PSYCHOSOMATIC OBSTETRICS & GYNECOLOGY, 2017 VOL. 38, NO. 3, 226–235.

<sup>2</sup>Nichols, H. et al., JNCI J Natl Cancer Inst, 2015, 1–8.

<sup>3</sup>Challapalli, A. et al., Clinical and Translational Radiation Oncology 10 (2018) 29–35.


<sup>4</sup>Abildgaard, J. et al., JNCI Cancer Spectrum, 2018, Vol. 0, No. 0.

<sup>5</sup>L. Johnson, et al. American Society for Reproductive Medicine, 2014 Vol 102 No. 3, Supplement, e249.

<sup>6</sup>Griffiths, E. et al: The Obstetrician & Gynaecologist, 2005: 7:23-27.

# Mechanism of Action



- Neurokinin B (NKB) belongs to a group of neuropeptides, called tachykinins or neurokinins, that includes substance-P (SP), neurokinin A (NKA), and two N-terminally extended forms of NKA, neuropeptide g and neuropeptide K
- The biological effects of tachykinins are mediated through specific receptors denoted NK1, NK2, and NK3
- NKB is the preferred endogenous ligand of tachykinin NK3 receptors
- The tachykinin NK3 receptors are located primarily in the brain, while a few receptors are also present in the peripheral nervous system (intestines, placenta)



# Clinical POC in VMS: NK3R Antagonist

- Fezolinetant is a NK3R antagonist being developed by Astellas for moderate-to-severe VMS

## Average Daily Hot Flash Frequency Reported as per FDA Guidance




### At Week 4:

- fezolinetant group: 14/40 patients have ZERO hot flash
- placebo group: 2/40 patients have ZERO hot flash

# Clinical POC in VMS: NK3R Antagonist

- Pavinetant (MLE4901) was a NK3R antagonist that was discontinued by Millendo for the treatment of polycystic ovary syndrome and menopausal hot flashes



**FIG. 2.** Hot flash frequency (A), severity (B), bother (C), and interference (D) outcomes: results are presented as percentage change with 95% CIs from baseline at each time point during the treatment period (ie, on day 3 of treatment, and then weekly mean total for each week (wk) of the 4-week treatment period for both placebo (white) and MLE4901 (gray). Minimum  $n = 33$ ; maximum  $n = 37$ . \* $P < 0.0001$ , # $P = 0.0006$ , ^ $P = 0.0011$ , + $P = 0.0001$ . Week 4 data adapted from Prague et al, *Lancet*, 2017<sup>18</sup>.

# Development Plan

- Acer is partnering with leading universities to design & conduct clinical trials to evaluate osanetant in various patient populations with iVMS
- These include patients with medically or surgically iVMS (may include any/all of the following):
  - Women who are BRCA+ and have had a PBSO
  - Men with HR+ Prostate Cancer receiving leuprolide
  - Women with HR+ Breast Cancer receiving tamoxifen
- Initial Phase 2 BRCA+ PBSO trial<sup>§</sup>:
  - Evaluate PK/PD and safety, including physiologic PD
  - Identify the optimal dosing strategy to advance into further efficacy studies in minimizing the iVMS symptoms

## Disease Overview

### ➤ **Broad-spectrum Antiviral**

- In vitro +/- in vivo data across multiple virus families, including coronavirus, filovirus, flavivirus, herpesvirus, togavirus, arenavirus, HIV, influenza

## Mechanism of Action

### ➤ **Host-directed Therapy**

- Restores cellular stress response by interrupting the viral-induced MDM2-P53 loop, by shepherding RPS14 from cytosol into the nucleus, thus inhibiting viral replication
- Few drugs in development that are host-directed; believed to be only drug exploiting this particular MOA

## Product Profile

### ➤ **Used previously in tens of thousands of humans as an antiprotozoal, emetic, and antiviral agent**

- Toxicity is related to cumulative dose
- Reasonable safety profile administered as injectable in humans up to 10 mg/kg cumulative dose

## The Opportunity

### ➤ **Pursuing multiple non-dilutive funding options**


- Proposed clinical trial to evaluate emetine in high-risk, symptomatic adult patients with COVID-19 infection not requiring hospitalization\*<sup>§</sup>
- Evaluating development pathways against other viruses utilizing animal rule / Medical Countermeasure (MCM) pathway<sup>§</sup>

# History

- Emetine is one of the main alkaloids found in ipecacuanha (ipecac) root
- Clinically, emetine hydrochloride was originally marketed in the U.S. as a topical anti-infective in dental applications (ca 1890s by Eli Lilly and Company)
- Later, emetine hydrochloride for injection gained market adoption as a specific treatment for amebic infections and was used for this purpose through the 1980s in the U.S. until its market displacement by metronidazole
- An oral formulation, syrup of ipecac, also contains emetine as one of its active ingredients
- Substantial clinical experience with emetine and emetine-containing products exists because of their introduction in the U.S. prior to the 1938 Food, Drug, and Cosmetic Act, and especially the development of an over-the-counter monograph for syrup of ipecac
- Its broad antiviral activity has only been discovered in the past decade
- Clinically, emetine has been used to treat approximately 700 patients (including pediatrics) with viral hepatitis<sup>1</sup> and varicella-zoster virus<sup>2</sup>

# Mechanism of Action

- Viral infections have developed evolutionary mechanisms for inhibiting the cellular stress response and promote ribosome biogenesis to facilitate viral replication
- **Host-directed Therapy:** Binding of emetine with RPS14 restores the cellular stress response, which results in blocking ribosome biogenesis and translation-elongation of viral mRNA in infected cells
- Emetine does not inhibit viral replication in null RPS14 cells
- Viral resistance believed to be extremely unlikely given unique MOA



In high-density infected cells (A) emetine induces (1) nuclear translocation of RPS14 (2) followed by RPS14 binding to MDM2 (3 & 4) resulting in disruption of the interaction between MDM2-p53 (6) and MDM2- viral IE2 (5 & 7), and by RPS14 ubiquitination and degradation (8). In low-density infected cells (B) although emetine induces (1) nuclear translocation of RPS14 (2), it is unable to interact with MDM2 (4) which is already bound to p53 to facilitate virus replication (3).

# In Vitro Data

- Nanomolar *in vitro* potency against a wide variety of both DNA- & RNA-replicating viruses

Virus Type	Antiviral Activity*	Reference
SARS-CoV-2 (Vero-E6)	<b>EC<sub>50</sub> = 0.007 µM</b>	Wang et al. Molecular Biomedicine 1:14 <a href="https://doi.org/10.1186/s43556-020-00018-9">https://doi.org/10.1186/s43556-020-00018-9</a> (2020).
SARS-CoV-2 (Caco-2)	<b>IC<sub>50</sub> = 0.47 µM</b>	Bojkova et al. Proteomics of SARS-CoV-2-infected host cells reveals therapy targets. Nature <a href="https://doi.org/10.1038/s41586-020-2332-7">https://doi.org/10.1038/s41586-020-2332-7</a> (2020).
SARS-CoV-2 (Vero-E6)	<b>EC<sub>50</sub> = 0.46 µM**</b>	Choy et al. Antiviral Research. 2020 Apr 3; pre-proof <a href="https://doi.org/10.1016/j.antiviral.2020.104786">https://doi.org/10.1016/j.antiviral.2020.104786</a>
SARS-CoV-2 (Vero-E6)	<b>EC<sub>50</sub> &lt; 0.01 µM</b>	Ianevski et al. 2020 May. Antiviral options against SARS-CoV-2 infection. <a href="https://doi.org/10.1101/2020.05.12.091165">doi.org/10.1101/2020.05.12.091165</a>
HCoV-OC43	<b>EC<sub>50</sub> = 0.30 / CC<sub>50</sub> = 2.69</b>	Shen et al. J Virol. 2019 May 29;93(12). pii: e00023-19. doi: 10.1128/JVI.00023-19.
HCoV-NL63	<b>EC<sub>50</sub> = 1.43 / CC<sub>50</sub> = 3.63</b>	
MERS-CoV	<b>EC<sub>50</sub> = 0.34 / CC<sub>50</sub> = 3.08</b>	
MHV-A59	<b>EC<sub>50</sub> = 0.12 / CC<sub>50</sub> = 3.51</b>	
MERS-CoV	<b>EC<sub>50</sub> = 0.014</b>	Dyall et al. Antimicrob Agents Chemother. 2014 Aug;58(8):4885-93. doi: 10.1128/AAC.03036-14.
SARS-CoV	<b>EC<sub>50</sub> = 0.051</b>	Yang et al. Cell Discov. 2018 Jun 5;4:31. doi: 10.1038/s41421-018-0034-1.
ZIKV-MR766	<b>IC<sub>50</sub> = 9.15e-009</b>	
ZIKV-FSS13025	<b>IC<sub>50</sub> = 1.072e-008</b>	
ZIKV-PRVABC59	<b>IC<sub>50</sub> = 9.591e-009</b>	
EBOV-Vero E6	<b>IC<sub>50</sub> = 16.9 nM</b>	Andersen et al. Viruses. 2019 Oct 18;11(10). pii: E964. doi: 10.3390/v11100964.
HSV-2	<b>EC<sub>50</sub> = 0.03 / CC<sub>50</sub> = 1.12</b>	
HMPV	<b>EC<sub>50</sub> = 0.14 / CC<sub>50</sub> = 1</b>	
HIV M184V	<b>EC<sub>50</sub> = 0.012 – 0.03</b>	Chaves Valadao et al. Molecules. 2015 Jun 22;20(6):11474-89. doi: 10.3390/molecules200611474.
HCMV	<b>EC<sub>50</sub> = 40 nM / CC<sub>50</sub> = 8 µM</b>	Mukhopadhyay et al. PLoS Pathog. 2016 Jun 23;12(6):e1005717. doi: 10.1371/journal.ppat.1005717.


EC<sub>50</sub> = concentration of a drug that gives half-maximal response. IC<sub>50</sub> = concentration of an inhibitor where the response is reduced by half. CC<sub>50</sub> = 50% cytotoxic concentration

\*EC<sub>50</sub> / CC<sub>50</sub> values = µM (unless otherwise noted)

\*\*For reference, the EC<sub>50</sub> of remdesivir is 23.15 µM at MOI 0.02; paper demonstrates that emetine is synergistic with remdesivir

# In Vivo Efficacy Data

## Zika virus<sup>1</sup>




### Emetine suppresses ZIKV virus load in vivo.

**a** Three-month-old SJL male mice were infected retro-orbitally with ZIKVBR followed by IP administration of emetine (1 mg/kg/day) for the next 6 days (N = 4 mice per group). Two groups of SJL mice (N = 4) received the same volume of vehicle buffers. Statistical analysis by two tailed t-test. \*\*p = 0.0014, \*\*\*p = 0.0005.

**b** Ifnar1<sup>-/-</sup> mice were dosed with emetine 1 mg/kg (E1, N = 6), 2 mg/kg (E2, N = 7), and PBS (VC, N = 8), respectively.


## Ebola virus<sup>1</sup>



### Emetine inhibits EBOV infection in vivo

**c** The survival curve of MA-EBOV infected mouse treated with 1 mg/kg emetine every day. Six to eight week-old female BALB/c mice were randomly assigned into groups (N = 6 animals). All the mice were challenged with a lethal dose of 1000 times the LD50 mouse adapted EBOV via IP treatments with either emetine (1 mg/kg/day) or PBS (same volume for the control group) were initiated at 3 h before the challenge and continued for up to 6 days post infection. Survival was monitored for 28 days post infection.

## Cytomegalovirus<sup>2</sup>



### Emetine achieves high tissue concentrations and is efficacious against MCMV replication.

**B** Quantitative real-time PCR of viral gB was performed on DNA extracted from blood at day 14 post infection. Emetine was administered orally starting 24 hpi or 72 hpi at 0.1 or 1.0 mg/kg every 3 days. GCV dose was 10 mg/kg/dose administered intraperitoneally twice daily.

# PK & Tox Data

- Non-clinical pharmacokinetic studies show that emetine rapidly concentrates in the tissues, reaching levels that are 1,000- to 3,000-fold greater than in the plasma
- Emetine has been detected in a variety of tissues, including the heart, liver, lungs, intestines, kidney, spleen, stomach, adrenals, and brain, with a long (days/weeks) tissue half-life
- However, the key target organs of toxicity identified in the literature are muscle and cardiac tissue. All identified studies (animals, in vitro, and humans) focused on muscle and cardiac effects
- Acute toxicity with emetine appears to be related to cumulative dose exposure, but also appears completely reversible ~3 weeks after cessation of therapy:

Species	Fatal Cumulative Dose	ROA
Mice	50-100 mg/kg	IP
Rats	10-25 mg/kg	IP
Rabbits	10-30 mg/kg	PO
Cats	10-25 mg/kg	PO
Dogs	6 mg/kg	IP
Humans	15-20 mg/kg	SQ

# Clinical Safety

- Patients with solid tumors treated with 1 mg/kg/day emetine daily via SC injection for 10 days (cumulative dose 650 mg) did not experience any notable toxicity<sup>1</sup>
- Electrocardiographic abnormalities were observed, but not often associated with significant cardiac symptoms<sup>2,3,4</sup>
  - T wave inversion (TWI) is the first to appear and the last to disappear
  - Q-T interval prolongation
  - The average time required for complete return of the tracing to normal is ~six weeks
- At higher cumulative doses (e.g.  $\geq 650$  mg): hypotension, tachycardia, cardiomyopathy, myocarditis, precordial pain, gallop rhythm (on auscultation), dyspnea, cardiac dilatation, congestive failure, and death have been reported<sup>5</sup>
- Toxicity with emetine appears to be cumulative-dose related and independent of schedule<sup>1,6</sup>
- Complete reversibility of cardiac adverse effects<sup>6</sup>

1 Mastrangelo et al. Cancer 31:1170-1175.

2 Banerjee et al J Assoc Physicians India 14:349-364.

3 Ramachandran et al. Ceylon Med J 18:138-143.

4 Moertel et al. Cancer Chemother Rep 58:229-232, 1974.

5 Bleasel et al. Pharmaceuticals 2020, 13, 51.

6 Siddiqui et al. Cancer Chemother Rep 57:423-428, 1973.

# Financial Overview

- Cash
  - \$5.8M as of December 31, 2020, combined with additional:
    - \$3.2M of net proceeds subsequently received from ATM stock sales and Lincoln Park stock purchase agreement as of March 1, 2021
    - \$1.0M nonrefundable payment and \$4.0M secured loan received from Relief Therapeutics on January 26, 2021 as per the ACER-001 Option Agreement
  - Expected to have sufficient capital to fund current operations into Q3 2021
- Capitalization as of March 1, 2021
  - 14.3M shares of common stock outstanding
  - 16.0M shares of common stock fully diluted
- \$100M invested through March 1, 2021
- \$4.0M secured 6% note due January 25, 2022

# Summary

- Acer's pipeline includes four programs:
  - **ACER-001** (a taste-masked, immediate release formulation of sodium phenylbutyrate) for the treatment of various inborn errors of metabolism, including urea cycle disorders (UCDs) and Maple Syrup Urine Disease (MSUD)
  - **EDSIVO™** (celiprolol) for the treatment of vascular Ehlers-Danlos syndrome (vEDS) in patients with a confirmed type III collagen (COL3A1) mutation
  - **ACER-801** (osanetant) for the treatment of induced Vasomotor Symptoms (iVMS)
  - **ACER-2820** (emetine) a host-directed therapy against a variety of infectious diseases
- Product candidates are believed to present a comparatively de-risked profile, having one or more of:
  - Favorable safety profile; clinical proof-of-concept data; mechanistic differentiation
  - Potential expedited paths for development through specific FDA-established programs
- Multiple anticipated key milestones:
 

✓ ACER-001 BE fed trial completed:	<b>Q1 2021</b>
• ACER-001 pre-NDA meeting with FDA*:	<b>Q2 2021</b>
• EDSIVO™ FDA meeting to discuss confirmatory evidence plan:	<b>Q2 2021</b>
• ACER-001 (UCDs) NDA submission**:	<b>Mid-2021</b>
• Osanetant IND submission:	<b>Q3 2021</b>
• Osanetant Phase 2 trial initiation***\$:	<b>Q4 2021</b>

\* Assuming successful completion of the ongoing development activities

\*\* Provided no additional data is requested by the FDA during pre-NDA meeting and ongoing development activities are successfully completed (including evaluation of long-term product stability data)

\*\*\* Subject to successful IND submission and clearance

\$ Subject to additional capital




acertherapeutics

## Reference Slides



# Maple Syrup Urine Disease (MSUD)


- MSUD is an inborn error of Branched-chain Amino Acid (BCAA) – leucine, isoleucine, valine – metabolism
  - Caused by deficiency of the mitochondrial Branched-chain Keto Acid Dehydrogenase complex (BCKDC)
  - ~800 patients in U.S., ~3,000 patients worldwide
  - MSUD Family Support Group has >500 patients
  - Part of newborn screening in U.S., UK, Germany
- High leucine levels lead to chronic and acute neurological damage
  - Lower IQ
  - Mental impairment (poor cognitive function)
  - Social impairment (poor executive function)
  - Metabolic decompensation (seizures and coma)
- A highly-restricted diet is the primary treatment
  - Consists of BCAA-free synthetic foods and formula
  - Very few foods have low BCAAs (fruits & vegetables)
  - Balancing act: enough BCAAs for growth & development



indicates  $p < 0.05$ , \*\*\*  $p < 0.001$  compared to the control group\*

# MSUD: Clinical POC Study

- Design: Open label pilot study<sup>1</sup> at Baylor College of Medicine – 3 healthy and 5 MSUD subjects with late onset disease
  - 3 days of steady-state protein diet\*; then 3 days of NaPB + diet\*
  - BCAAs and BCKAs determined at day 3 of each study period (4 time points)
- Results: NaPB showed a statistically significant reduction of leucine in all 3 healthy subjects ( $p < 0.05$ ) and 3 out of 5 MSUD patients ( $p < 0.05$  in responders)
  - ~30% reduction (28-34%) in leucine in MSUD responders
  - Clinicians view >20-30% ↓ as clinically meaningful\*\*
- Comments: Despite the short treatment duration (3 days) NaPB showed statistically significant (intra-subject) reduction in leucine in 75% of the subjects



Brunetti-Pierri et al., Hum Mol Genet. 2011 February 15; 20(4): 631–640

# MSUD: Market Opportunity

- About 1,000 MSUD patients in the U.S., ~3,000 WW\*
  - 20-25% MSUD patients in U.S. are Mennonite; incidence up to 1/380
  - Ashkenazi Jewish population; incidence of 1/26,000
- No treatments currently approved for MSUD
- Early treatment may help reduce the rate of neuropsychological comorbidities and optimize growth\*\*
- MSUD specialists recognize NaPB's potential effectiveness, yet tolerability is a concern\*\*\*
- Anticipate initiation of clinical studies in MSUD in late 2021\$

\* <https://www.ncbi.nlm.nih.gov/books/NBK1319/>

\* \*Molecular Genetics and Metabolism Reports 15 (2018).

\*\*\* Acer Therapeutics: US Market Research – 2014.

\$ Subject to additional capital